In BT-474 tumor-bearing animals (tumor volumes at treatment start: 40-212 mm3), HER2 α-DOTA-PRIT led to 7/19 (37%) complete response (CR) and significantly extended survival compared with mice treated with controls (Figure 4C and 4D). The gene discussed is ERBB2; the disease is neoplasm.